Champions Oncology, Inc. is a preclinical and clinical research services provider. The Company is engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs through its translational oncology solutions. This technology ranges from computational-based discovery platforms, oncology software solutions, and proprietary experimental tools such as in vivo, ex vivo and biomarker platforms. Utilizing its TumorGraft Technology Platform (the Platform), it provides select services to pharmaceutical and biotechnology companies seeking personalized approaches to drug development. It also sells Lumin Bioinformatics (Lumin), an oncology data-driven software program which contains comprehensive information derived from its research services and clinical studies. Lumin leverages a large data center coupled with analytics and artificial intelligence to provide a robust tool for computational cancer research.
成長中
同社は成長フェーズにあり、最新の年間収益はUSD 56.94Mに達しています。
黒字転換
同社は黒字転換を果たし、最新の年間純利益はUSD 4.70Mです。%!(EXTRA int=2)
割高
同社の最新のPEは19.08で、過去3年間の水準と比較して高値圏にあります。
機関投資家の売り越し
最新の機関投資家の保有株数は10.40M株で、前四半期比で1.68%減少しています。
バンガードが保有
スター投資家バンガードは本銘柄を327.03K株保有しています。
市場活動が低調
同社への投資家の関心は低下しており、20日間の売買回転率は-0.11です。